S
Senticell
United States · Biotech
Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells.
Product and customers
Its blood-sample platform analyzes RBC-bound and circulating DNA, RNA, and protein biomarkers to detect disease signals that plasma-only testing may miss, with initial focus on cancer. The company is advancing clinical validation through prospective oncology studies with Penn Medicine; it remains a developing diagnostics platform.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed | $7M | Capital Factory — ParticipantEvoce Capital — ParticipantScalpel Ventures — ParticipantThe Venture City — Participant |